Evidence map›Paper›PMID 41817610›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2026

Transcatheter mitral valve edge-to-edge repair for severe mitral regurgitation in patients with HFpEF phenotype.

Johannes Dohr, Clemens Metze, Maria Isabel Körber, Matthieu Schäfer, Stephan Nienaber, Jonathan Curio, Richard Nies, Stephan Baldus, Roman Pfister, Christos Iliadis

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Johannes DohrDepartment III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0009-0009-3319-1337
Clemens MetzeDepartment III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Maria Isabel KörberDepartment III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Matthieu SchäferDepartment III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Stephan NienaberDepartment III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Jonathan CurioDepartment III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Richard NiesDepartment III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Stephan BaldusDepartment III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Roman PfisterDepartment III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Christos IliadisDepartment III for Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. christos.iliadis@uk-koeln.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe increasing prevalence of heart failure with preserved ejection fraction (HFpEF) is often accompanied by mitral regurgitation (MR). Transcatheter edge-to-edge repair (M-TEER) is established for treating MR in heart failure with reduced ejection fraction (HFrEF), but its impact in patients with HFpEF phenotype is unclear.

aimTo investigate the effect of M-TEER in patients with HFpEF phenotype and concomitant MR based on diagnostic criteria according to current ESC guidelines and established HFpEF scores.

methods181 patients with severe MR underwent M-TEER at our center with HFpEF phenotype. Echocardiography, symptom burden (NYHA class), quality of life (MLWHFQ, SF-PCS, and functional capacity (6MWD) were assessed before and 30 days after M-TEER. Survival and rehospitalisation rates were assessed at long-term follow-up.

resultsM-TEER in patients with HFpEF phenotype significantly reduced MR grade and improved symptom burden, quality of life, and exercise capacity. Patients with either primary or secondary MR experienced clinically relevant symptomatic improvement for MLWHFQ (69%) and SF-PCS (60%) as well clinically relevant increase (44%) of the 6MWD. The clinical outcome between patients with primary or secondary MR was comparable. Severe tricuspid regurgitation (TR) complicating HFpEF was independently linked to an increased mortality risk (HR 3.66, 95%CI 1.32-10.15, p = 0.013).

conclusionM-TEER is an effective treatment for both severe primary and secondary MR in patients with HFpEF phenotype, significantly reducing MR and improving symptoms. The independent association of severe TR with increased all-cause mortality highlights the importance of timely intervention to prevent right heart failure and worse outcomes.

Indexed as

Heart failure with preserved ejection fractionMitral regurgitationTranscatheter edge-to-edge repairValvular heart disease

Identifiers

PMID41817610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.